Validation study of risk classification in patients with castration-resistant prostate cancer

Validation study of risk classification in patients with castration-resistant prostate cancer - Validation study of CRPC risk classification

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011969

Enrollment

100

Registered

2013-10-07

Start date

2011-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -confirmed histological PCa diagnosis -refractory to androgen deprivation therapy with combined androgen blockade, anti-androgen withdrawal, and anti-androgen substitution -refractory to estramustine phosphate -received 2 or more cycles of docetaxel -obtained written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: -had insufficient clinical data for risk classification

Design outcomes

Primary

Measure	Time frame
Overall survival between the risk groups	—

Secondary

Measure	Time frame
Prostate-specific antigen responses between the risk groups	—

Countries

Japan

Contacts

Public ContactKazuhiko Nakano

Jichi Medical University Department of Urology

nknkzhk@jichi.ac.jp0285-58-7379

Outcome results